China Shineway Pharmaceutical Group Limited
CSWYF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $3 | $0 | $0 | $0 |
| % Growth | 1,115.8% | 98% | -16.9% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | $3 | $0 | $0 | $0 |
| % Margin | 74.9% | 75.3% | 75.1% | 75.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $1 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $0 | $0 | $0 |
| Operating Income | $1 | $0 | $0 | $0 |
| % Margin | 21.9% | 26.9% | 18.1% | 24.4% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $1 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $1 | $0 | $0 | $0 |
| % Margin | 21.6% | 30% | 22.6% | 20.5% |
| EPS | 0.996 | 0.114 | 0.043 | 0.047 |
| % Growth | 772% | 165% | -8.9% | – |
| EPS Diluted | 0.996 | 0.114 | 0.043 | 0.047 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | $0 | $0 | $0 |
| % Margin | 32.4% | 30.7% | 21.9% | 28% |